Sunovion Pharmaceuticals Inc. is a research-based pharmaceutical company dedicated to discovering, developing and commercializing scientifically advanced therapeutic products that are focused on helping patients suffering from central nervous system and respiratory disorders, as well as other illnesses.
A wholly-owned subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), Sunovion was formed following the merger of DSP's two U.S.-based operations, Sepracor Inc. and Dainippon Sumitomo Pharma America, Inc. The company name, which is representative of the life-affirming energy of the sun and the power of innovation, reflects Sunovion's portfolio of currently marketed pharmaceutical products and pipeline candidates; and serves to emphasize the company's ongoing commitment to improve the lives of patients everywhere.
|11/18/13||Sunovion Pharmaceuticals Inc., the COPD Foundation and Caring.com Join Forces to Support COPD Family Caregivers|
|11/8/13||Sunovion Pharmaceuticals Inc. Announces FDA Approval of Aptiom® (eslicarbazepine acetate) as Once-Daily Adjunctive Treatment of Partial-Onset Seizures|
|11/1/13||Sunovion Annouces Publication of Two Pivotal Studies Supporting FDA Approval of Latuda® (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients with Bipolar Depression in The American Journal of Psychiatry|
|10/29/13||Sunovion Presents Data at CHEST 2013 from a One-year, Large Simple Safety Study of BROVANA® (arformoterol tartrate) Inhalation Solution|
|10/4/13||Sunovion Launches Second Annual Community Service Day to Give Back to Greater Boston Communities and Support Causes Nationwide|
|9/17/13||Sunovion Reports Eslicarbazepine Acetate Meets Primary Endpoint in Two Phase 3 Monotherapy Studies for Partial-onset Seizures in Adults with Epilepsy|
|8/13/13||Sunovion Pharmaceuticals Inc. and Afraxis, Inc. Announce Novel Drug Discovery Partnership|
|6/28/13||Sunovion Pharmaceuticals Inc. Announces FDA Approval of Latuda® (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients with Bipolar Depression|
|5/21/13||Sunovion Pharmaceuticals Inc. Presents Data Showing 12 Months of Latuda® (lurasidone HCl) Treatment Resulted in Higher Remission Rates in Adult Patients with Schizophrenia Compared to Seroquel XR® (quetiapine XR)|
|5/20/13||Sunovion Pharmaceuticals Inc. Announces Data Showing Latuda® (lurasidone HCl) was Associated with Low Rates of Weight and Metabolic Changes in Patients with Depressive Episodes Associated with Bipolar I Disorder|
|5/20/13||Sunovion Presents Results from a One-year, Large Simple Safety Study of BROVANA® (arformoterol tartrate) Inhalation Solution|
|5/16/13||Sunovion to Present Three Posters on Results of One-year Large Simple Safety Study for BROVANA® (arformoterol tartrate) Inhalation Solution at 2013 ATS International Conference|
|2/27/13||Sunovion Announces FDA Acceptance for Review of New Drug Application Resubmission for STEDESA® (eslicarbazepine acetate) as a Once-Daily Adjunctive Therapy for Partial-onset Seizures in Adults with Epilepsy|
|2/25/13||Sunovion Presents New Analyses that Continue to Support ZETONNA® (ciclesonide) Nasal Aerosol's Efficacy in SAR and PAR|